BMS Files Ipilimumab With FDA And EMA, Positioning It For Launch Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, the CTLA-4 inhibitor would be the first new drug for the treatment of metastatic melanoma in over a decade.
You may also be interested in...
Bristol Melanoma Drug's Advisory Panel Delayed Following Review Date Delay
Additional Phase III data for ipilimumab might be available by next year, and an early March advisory committee date now looks likely, given the rescheduled PDUFA date of March 26, 2011.
Bristol Melanoma Drug's Advisory Panel Delayed Following Review Date Delay
Additional Phase III data for ipilimumab might be available by next year, and an early March advisory committee date now looks likely, given the rescheduled PDUFA date of March 26, 2011.
Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab
Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.